Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study on the Effectiveness of OSAG 101 (Theraloc) [nimotuzumab] in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents

Next Previous
Trial Profile

Phase III Study on the Effectiveness of OSAG 101 (Theraloc) [nimotuzumab] in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Glioma
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncoscience

    • Most Recent Events

    • 29 Oct 2009 YM Biosciences announced in a media release, that updated results were presented by Oncoscience AG, at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP) held in Sao Paulo, Brazil from October 5th-9th, 2009.
    • 09 Oct 2009 Oncoscience presents results for the first time at the World's Convention for Pediatric Oncology.
    • 30 May 2008 Tolerability results presented at 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top